EA201690299A1 - СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ - Google Patents
СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВInfo
- Publication number
- EA201690299A1 EA201690299A1 EA201690299A EA201690299A EA201690299A1 EA 201690299 A1 EA201690299 A1 EA 201690299A1 EA 201690299 A EA201690299 A EA 201690299A EA 201690299 A EA201690299 A EA 201690299A EA 201690299 A1 EA201690299 A1 EA 201690299A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptides
- amino acid
- stabilization
- containing polypeptides
- region
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
В настоящем изобретении предложены полипептиды, содержащие Fc-область антитела, которая имеет делецию по меньшей мере одного остатка цистеина в шарнирной области и замену по меньшей мере одной аминокислоты на поверхности домена СН3 на остаток аминокислоты, содержащий сульфгидрильную группу. Также предложены гибридные Fc-белки и антитела, содержащие такие полипептиды, нуклеиновые кислоты и векторы, кодирующие указанные полипептиды, а также клетки-хозяева и способы получения указанных полипептидов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361860800P | 2013-07-31 | 2013-07-31 | |
PCT/US2014/048908 WO2015017548A2 (en) | 2013-07-31 | 2014-07-30 | Stabilization of fc-containing polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690299A1 true EA201690299A1 (ru) | 2016-11-30 |
EA035319B1 EA035319B1 (ru) | 2020-05-27 |
Family
ID=52432568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690299A EA035319B1 (ru) | 2013-07-31 | 2014-07-30 | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ |
Country Status (15)
Country | Link |
---|---|
US (2) | US20160193295A1 (ru) |
EP (1) | EP3027647A4 (ru) |
JP (2) | JP2016526909A (ru) |
KR (2) | KR20160034404A (ru) |
CN (1) | CN105658664A (ru) |
AU (3) | AU2014296215A1 (ru) |
BR (1) | BR112016002219A2 (ru) |
CA (1) | CA2919076C (ru) |
CL (1) | CL2016000232A1 (ru) |
EA (1) | EA035319B1 (ru) |
HK (1) | HK1224203A1 (ru) |
IL (1) | IL243690B (ru) |
MX (2) | MX2016001165A (ru) |
SG (1) | SG11201600734YA (ru) |
WO (1) | WO2015017548A2 (ru) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AU2015339130C1 (en) * | 2014-10-31 | 2021-03-18 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
WO2016100788A1 (en) | 2014-12-19 | 2016-06-23 | Alkermes, Inc. | Single chain fc fusion proteins |
RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
WO2017205014A1 (en) | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
JP7084881B2 (ja) | 2016-06-22 | 2022-06-15 | アルカームス インコーポレーテッド | Il-10の免疫刺激特性および抗炎症特性を調節するための組成物および方法 |
CN116970060A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
EP3576789A4 (en) * | 2017-02-01 | 2020-11-25 | Centrymed Pharmaceuticals Inc. | MONOMER HUMAN IGG1-FC AND BISPECIFIC ANTIBODIES |
TWI832818B (zh) * | 2017-07-07 | 2024-02-21 | 南韓商韓美藥品股份有限公司 | 新穎的治療性酵素融合蛋白及其用途 |
CA3071337A1 (en) * | 2017-08-15 | 2019-02-21 | Kindred Biosciences, Inc. | Igg fc variants for veterinary use |
CN107540748B (zh) * | 2017-09-15 | 2020-07-14 | 北京伟杰信生物科技有限公司 | 长效重组猪fsh融合蛋白及其制备方法与应用 |
NZ765453A (en) * | 2017-12-22 | 2024-03-22 | Hanmi Pharmaceutical Co Ltd | Therapeutic enzyme fusion protein having novel structure and use thereof |
TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
MX2021001353A (es) | 2018-08-03 | 2021-04-13 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cldn18.2 y cd3. |
KR102200773B1 (ko) * | 2018-09-19 | 2021-01-12 | 주식회사 바이오앱 | 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물 |
US10947278B2 (en) * | 2018-09-19 | 2021-03-16 | Bioapplications Inc. | Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof |
KR102148405B1 (ko) * | 2018-09-19 | 2020-08-27 | 주식회사 바이오앱 | 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법 |
US20220144916A1 (en) * | 2019-02-12 | 2022-05-12 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
WO2020243338A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
JP2022535060A (ja) | 2019-06-07 | 2022-08-04 | アムジエン・インコーポレーテツド | 選択的に切断可能なリンカーを有する二重特異性結合構築物 |
US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
CN113372438A (zh) * | 2020-02-25 | 2021-09-10 | 希森美康株式会社 | 改造抗体及其制造方法、以及提高抗体的热稳定性的方法 |
CN111285936A (zh) * | 2020-03-11 | 2020-06-16 | 北京双赢科创生物科技有限公司 | 靶向肿瘤的酸性敏感纳米肽段及其应用 |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
EP4153633A1 (en) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Mageb2 binding constructs |
WO2022032660A1 (zh) * | 2020-08-14 | 2022-02-17 | 武汉友微生物技术有限公司 | 新型冠状病毒rbd融合蛋白 |
CN114426974B (zh) * | 2020-10-29 | 2023-11-21 | 洛阳普泰生物技术有限公司 | 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段 |
KR20230097061A (ko) * | 2020-11-02 | 2023-06-30 | 아트라러스, 인크. | Sap fc 융합 단백질 및 사용 방법 |
BR112023008629A2 (pt) | 2020-11-06 | 2023-10-03 | Amgen Inc | Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3 |
WO2022120286A1 (en) * | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
CN115925984A (zh) * | 2021-08-24 | 2023-04-07 | 广东东阳光药业有限公司 | Gdf15融合蛋白及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
AU751659B2 (en) * | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
WO2006028936A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
WO2007059782A1 (en) * | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
JP2013511281A (ja) * | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Fc |
WO2012078688A2 (en) | 2010-12-06 | 2012-06-14 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
-
2014
- 2014-07-30 MX MX2016001165A patent/MX2016001165A/es unknown
- 2014-07-30 CA CA2919076A patent/CA2919076C/en active Active
- 2014-07-30 EA EA201690299A patent/EA035319B1/ru not_active IP Right Cessation
- 2014-07-30 AU AU2014296215A patent/AU2014296215A1/en not_active Abandoned
- 2014-07-30 US US14/909,431 patent/US20160193295A1/en not_active Abandoned
- 2014-07-30 IL IL243690A patent/IL243690B/en unknown
- 2014-07-30 WO PCT/US2014/048908 patent/WO2015017548A2/en active Application Filing
- 2014-07-30 EP EP14832297.7A patent/EP3027647A4/en active Pending
- 2014-07-30 BR BR112016002219A patent/BR112016002219A2/pt not_active Application Discontinuation
- 2014-07-30 JP JP2016531860A patent/JP2016526909A/ja active Pending
- 2014-07-30 KR KR1020167004786A patent/KR20160034404A/ko not_active IP Right Cessation
- 2014-07-30 CN CN201480046222.5A patent/CN105658664A/zh active Pending
- 2014-07-30 KR KR1020237032656A patent/KR20230141929A/ko active Application Filing
- 2014-07-30 SG SG11201600734YA patent/SG11201600734YA/en unknown
-
2016
- 2016-01-27 MX MX2022008013A patent/MX2022008013A/es unknown
- 2016-01-28 CL CL2016000232A patent/CL2016000232A1/es unknown
- 2016-11-01 HK HK16112553.6A patent/HK1224203A1/zh unknown
-
2019
- 2019-03-08 US US16/297,494 patent/US20190192628A1/en active Pending
-
2020
- 2020-01-17 AU AU2020200329A patent/AU2020200329A1/en not_active Abandoned
- 2020-09-25 JP JP2020160475A patent/JP7344858B2/ja active Active
-
2022
- 2022-02-22 AU AU2022201204A patent/AU2022201204A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2919076C (en) | 2024-01-30 |
HK1224203A1 (zh) | 2017-08-18 |
JP7344858B2 (ja) | 2023-09-14 |
EP3027647A4 (en) | 2017-01-04 |
JP2016526909A (ja) | 2016-09-08 |
JP2021019598A (ja) | 2021-02-18 |
AU2020200329A1 (en) | 2020-02-06 |
WO2015017548A3 (en) | 2015-11-05 |
KR20160034404A (ko) | 2016-03-29 |
US20190192628A1 (en) | 2019-06-27 |
EP3027647A2 (en) | 2016-06-08 |
KR20230141929A (ko) | 2023-10-10 |
AU2014296215A1 (en) | 2016-02-11 |
EA035319B1 (ru) | 2020-05-27 |
CN105658664A (zh) | 2016-06-08 |
IL243690B (en) | 2022-09-01 |
SG11201600734YA (en) | 2016-02-26 |
AU2022201204A1 (en) | 2022-03-17 |
US20160193295A1 (en) | 2016-07-07 |
BR112016002219A2 (pt) | 2017-09-12 |
CA2919076A1 (en) | 2015-02-05 |
CL2016000232A1 (es) | 2016-09-02 |
IL243690A0 (en) | 2016-04-21 |
WO2015017548A2 (en) | 2015-02-05 |
MX2016001165A (es) | 2016-06-29 |
MX2022008013A (es) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
BR112018011073A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização | |
EA201591700A1 (ru) | Гибридные белки апелина и их применение | |
EA201791134A1 (ru) | Полипептиды химерного фактора viii и их применение | |
MX2020001227A (es) | Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes. | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
SA518391704B1 (ar) | C5 أجسام مضادة لـ وطرق لاستخدامها | |
EA201691304A1 (ru) | АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
WO2013142859A3 (en) | Fusion proteins of superfolder green fluorescent protein and use thereof | |
CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
EA201691589A1 (ru) | Стабилизированные основанные на фибронектине каркасные молекулы | |
EA201892588A1 (ru) | Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации | |
UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
UY37752A (es) | Proteínas de unión al antígeno anti-jagged1 | |
MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
EA201790241A1 (ru) | Эффективная селективность в отношении рекомбинантных белков | |
AU2019479791B2 (en) | Anti-CTLA-4 antibody and use thereof | |
AR090915A1 (es) | Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg | |
NZ750009A (en) | Antibodies comprising chimeric constant domains |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |